• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

    2/18/25 10:50:00 AM ET
    $ARDT
    $DXR
    Hospital/Nursing Management
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ARDT alert in real time by email
    • Newly appointed President Walter D. Conwell, MD, MBA, poised to broaden reach with healthcare organizations nationwide
    • Two board members bring additional expertise in health equity innovation and regulation
    • Leadership team committed to TruLite's exponential growth potential as only health equity solution addressing clinical bias at point of care

    TruLite Health, developer of the only health equity solution to remediate clinical bias, has expanded the leadership team as the company strengthens artificial intelligence capabilities and scales to meet the needs of hospital systems, educational institutions and other healthcare organizations nationwide.

    Walter D. Conwell, MD, MBA, now serves as president. Previously serving as chief diversity and inclusion officer and associate dean for faculty development at the Morehouse School of Medicine (MSM) in Atlanta, Conwell is lauded for his health equity expertise, having led the development and implementation of a comprehensive equity strategic framework for the institution. He is also a practicing internal medicine, pulmonary disease, critical care medicine and sleep medicine physician. Conwell has published numerous peer-reviewed articles on medical education, health economics and health equity.

    Conwell is focused on expanding the awareness and implementation of TruLite's innovative software, Truity™, which addresses clinical bias at the point of care by driving patient-specific clinical, social and behavioral interventions that lead to improved healthcare outcomes and costs.

    "Through explainable AI and machine learning, TruLite has the potential to evolve health equity initiatives in a way no other solution can," said Conwell. "To help lead an organization through such transformational change is an incredible opportunity, and I'm eager to leverage my medical and institutional background to significantly advance health equity in this country."

    In addition to appointing a new president, TruLite has added two board members:

    • Edmondo Robinson, MD, MBA, is a national leader in digital health and innovation with over 25 years of experience in healthcare delivery, management and leadership. He is a member of the board of directors at Ardent Health Services (NYSE:ARDT) and the University of Vermont Health Network.
    • Caleb DesRosiers, JD, MPA, is a pharmaceutical and managed care services executive with experience in venture capital, regulatory affairs and public policy. He is a member of the board of directors of Daxor Corp (NASDAQ:DXR).

    "We have the right team and technology in place to significantly address health equity at grand scale," said TruLite Founder and CEO Alan Roga, MD. "The demand for our solution is growing as more healthcare organizations understand the multi-faceted impact of health equity and prioritize clinical strategies to improve care while lowering overall costs. Enhancing the expertise on our own team is a pivotal move amid growth opportunities."

    Leveraging the largest health equity knowledge base, TruLite's Truity software directly integrates into electronic health records (EHRs). It provides patient-specific actions and interventions for clinicians, care teams and patients within the workflow. This integration empowers providers to improve equity at the point of care and aligns with regulatory drivers, including the Joint Commission, Centers for Medicare and Medicaid and Food and Drug Administration.

    Learn how Truity works and more about the health equity champions behind TruLite's innovations.

    About TruLite Health

    TruLite Health has developed the first and only health equity platform designed to address systemic inequities at the point of care. Its innovative software – Truity™ – leverages a unique health equity knowledge base, AI and machine learning to drive targeted interventions for diverse patient populations, improve outcomes and reduce costs. More at trulitehealth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250218781810/en/

    Lena Vivion

    TruLite Health

    (602) 617-7903

    [email protected]

    Get the next $ARDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARDT
    $DXR

    CompanyDatePrice TargetRatingAnalyst
    Ardent Health Inc.
    $ARDT
    11/17/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Ardent Health Inc.
    $ARDT
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    Ardent Health Inc.
    $ARDT
    10/14/2025$19.00Neutral
    Goldman
    Ardent Health Inc.
    $ARDT
    9/10/2025$17.00Buy
    UBS
    Ardent Health Inc.
    $ARDT
    7/16/2025$14.60Neutral → Underperform
    BofA Securities
    Ardent Health Inc.
    $ARDT
    12/17/2024$20.00Neutral
    Analyst
    Ardent Health Inc.
    $ARDT
    11/6/2024$22.00 → $19.00Buy → Neutral
    BofA Securities
    Ardent Health Inc.
    $ARDT
    10/11/2024$24.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ARDT
    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

    OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater. The research investigated the relationship between traditional clinical scoring methods and direct, in-vivo measurement of albumin escape using Daxor's Blood Volume Analyzer (BV

    3/26/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

    Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient's total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annua

    3/17/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

    Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings. This streamlined workflow positions Daxor to address the high costs associated with the more than five m

    3/10/26 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $ARDT
    $DXR
    SEC Filings

    View All

    Amendment: SEC Form N-CEN/A filed by Daxor Corporation

    N-CEN/A - DAXOR CORP (0000027367) (Filer)

    4/2/26 1:35:05 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form 40-17F2 filed by Daxor Corporation

    40-17F2 - DAXOR CORP (0000027367) (Subject)

    3/31/26 3:39:41 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Ardent Health Inc. filed SEC Form 8-K: Leadership Update

    8-K - Ardent Health, Inc. (0001756655) (Filer)

    3/27/26 4:15:02 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    $ARDT
    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Michel Robert J bought 3,000 units of Daxor Common Stock, increasing direct ownership by 18% to 20,050 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:46:46 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Scientific Officer Feldschuh Jonathan Adam bought 18,000 units of Daxor Common Stock, increasing direct ownership by 50% to 53,908 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    12/11/25 3:41:44 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $ARDT
    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bulgarelli Peter J.

    4 - Ardent Health, Inc. (0001756655) (Issuer)

    4/2/26 4:51:28 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Havdala Ellen

    4 - Ardent Health, Inc. (0001756655) (Issuer)

    4/2/26 4:51:07 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by Sotir Mark R

    4 - Ardent Health, Inc. (0001756655) (Issuer)

    4/2/26 4:50:39 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    $ARDT
    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ardent Health downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Ardent Health from Overweight to Sector Weight

    11/17/25 9:39:33 AM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    Ardent Health downgraded by Morgan Stanley

    Morgan Stanley downgraded Ardent Health from Overweight to Equal-Weight

    11/14/25 9:48:25 AM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    Goldman initiated coverage on Ardent Health with a new price target

    Goldman initiated coverage of Ardent Health with a rating of Neutral and set a new price target of $19.00

    10/14/25 8:47:11 AM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    $ARDT
    $DXR
    Leadership Updates

    Live Leadership Updates

    View All

    Ardent Health Appoints Chief Development Officer to Lead Strategic Growth

    Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Chris Schoeplein as chief development officer. In this new role, Schoeplein will lead development efforts across Ardent's existing markets and support the organization's expansion into new regions. He will be responsible for driving growth across inpatient and outpatient care settings through acquisitions, partnerships and joint ventures. Additionally, he will guide due diligence, market intelligence and integration planning to advance Ardent's long-term growth strategy. "We are excited to welcome Chris to Ardent at a pivotal time in our gr

    5/19/25 4:30:00 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    Ardent Health Appoints Robert DeMichiei to Board of Directors

    Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial officer at the University of Pittsburgh Medical Center (UPMC) from 2004 to 2020. During his tenure, he played a pivotal role in driving UPMC's financial growth and led numerous strategic initiatives, including mergers and acquisitions, supply chain management, and revenue cycle improvements. Prior to joining U

    4/3/25 5:27:00 PM ET
    $AP
    $ARDT
    $HCAT
    Fluid Controls
    Industrials
    Hospital/Nursing Management
    Health Care

    Ardent Health Announces Appointment of Chief Operating Officer and Senior Leadership Promotions

    Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Dave Caspers as chief operating officer. In this new role, Caspers will oversee operations across Ardent Health, which includes 30 hospitals and 280 sites of care in six states. He will be responsible for executing on strategic growth initiatives and driving operational excellence at an enterprise level. Caspers will also lead efforts to further optimize and scale the company's consumer-centric operating model across new and existing markets. "We are pleased to welcome Dave to Ardent," said Ardent Health President and CEO Marty Bonick. "His

    3/31/25 4:30:00 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    $ARDT
    $DXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ardent Health Partners Inc.

    SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)

    11/14/24 6:07:29 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Ardent Health Partners Inc.

    SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)

    11/14/24 4:45:09 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Ardent Health Partners Inc.

    SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)

    11/14/24 4:27:52 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    $ARDT
    $DXR
    Financials

    Live finance-specific insights

    View All

    Ardent Health Announces Fourth Quarter and Full Year 2025 Results Conference Call and Webcast Date

    Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its fourth quarter and full year 2025 results after the market closes on Wednesday, March 4, 2026. A conference call will be held the following day, Thursday, March 5, 2026, at 10 a.m. ET to review the Company's financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent's website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in o

    2/12/26 4:30:00 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    Ardent Health Announces Third Quarter 2025 Results Conference Call and Webcast Date

    Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its third quarter 2025 results after the market closes on Wednesday, November 12, 2025. A conference call will be held the following day, Thursday, November 13, 2025, at 9 a.m. ET to review the Company's financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent's website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to

    10/22/25 4:30:00 PM ET
    $ARDT
    Hospital/Nursing Management
    Health Care

    Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

    Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it perfectly encapsulates the spirit behind our latest achievements. We are thrilled to share that this persistence has culminated in a truly transformative moment for our company, marking an important

    9/2/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care